Categories
Latest News
- Toft Group Welcomes Julie Visser as Executive Career Coach and Executive Search Leader10/02/2019 - 2:15 PM
- Toft Group Executive Search Places Ellen Lubman on Board of Advisors at TMRW Life Sciences, Inc. in New York, NY09/12/2019 - 11:06 AM
- Toft Group Executive Search Places Chris Cournoyer on Board of Directors for CareDx, Inc. in Brisbane, CA08/27/2019 - 10:12 AM
Toft Group Executive Search Places Lori Batta as Chief Commercial Officer at TMRW Life Sciences, Inc. in New York, NY
/in Press Releases /by ToftgroupToft Group Executive Search, a global life sciences and healthcare executive recruiting firm, has successfully placed Lori Batta as Chief Commercial Officer at TMRW Life Sciences, Inc. in New York, NY.
Lori Batta was previously Chief Commercial Officer at Celmatix, Inc., a next generation women’s health company. Prior to Celmatix, Batta served as Senior Vice President, Business Development and Strategic Alliances at Good Start Genetics (GSG), where she led the company’s global business development strategy. During her time at GSG, Batta was responsible for the launch of the first next-generation sequencing carrier screen and drove more than $100M in revenue in its first three years in the market.
Batta also served as Senior Director, Commercial with Javelin Pharmaceutical, where she directed regulatory and commercialization strategy for the Javelin Pain Franchise for three late-stage specialty pain products. Before Javelin, she served as Vice President of Sales and Marketing for MDR Specialty Pharma, and Vice President of Sales, Reproductive Health for EMD Serono.
Batta holds a B.A. in Biology from College of St. Elizabeth, Convent Station, NJ.
About TMRW
In coming decades, a rapidly scaling fertility industry and increased access to IVF therapies will be responsible for nearly 300 million global births—almost all of which will rely upon frozen fertility cells. To meet this rapidly growing demand, TMRW has created the first fully Robotic Process Automation (RPA) platform designed specifically for IVF. Already experiencing rapid market enthusiasm, TMRW is poised to become the global standard for cryo-preservation and fertility cell management. IVF clinicians have embraced the concept of TMRW’s risk-mitigating RPA platform as a replacement for current less sophisticated analog IVF cryo-management systems. TMRW provides the world’s first complete RFID cryo-temperature compatible digital chain of custody for all fertility cells—including embryos and gametes. TMRW software is constantly vigilant and automates 17,000 daily environmental “health checks” that ensure the safety and security of the world’s most precious cells.
TMRW’s co-founders, Joshua Abram, Alan Murray and Dr. Jeff Port, are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion. www.tmrw.org
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego and Boston.
Toft Group Executive Search Places Peg Taylor as Vice President, Clinical Operations at Adicet Bio, Inc. in Menlo Park, CA
/in Press Releases /by ToftgroupToft Group Executive Search, a global life sciences and healthcare executive recruiting firm, has successfully placed Peg Taylor as Vice President, Clinical Operations at Adicet Bio, Inc. in Menlo Park, CA.
Peg Taylor most recently served as Senior Director, Clinical Operations at Nektar Therapeutics. Previously, she served in progressive clinical roles at Genentech, most recently as Program Group Director. There, she led the program execution of all Clinical Operations for a portfolio of molecules in early development.
Prior to Genentech, Taylor was Senior Director at Bayhill Therapeutics where she led clinical operations for a virtual biotech company focused on autoimmune disease assets. Earlier, she served as Oncology Clinical Program Director for Quintiles (now IQVIA), where she supported various studies focused on tumors including NSCLC, Glioblastoma, GI Stromal Tumors and MBC.
Taylor holds a B.S. in Nutrition Science from University of California, Davis.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet’s gamma delta T cell allogeneic platform technology.
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego and Boston.
Toft Group Executive Search Successfully Places Jessica M. Riley, Ph.D. as Vice President of Companion Diagnostics at PathAI in Boston, MA
/in Press Releases /by ToftgroupToft Group Executive Search, a global life sciences and healthcare executive recruiting firm, has successfully placed Jessica M. Riley, Ph.D. as Vice President of Companion Diagnostics at PathAI in Boston, MA.
Dr. Jessica Riley served as Senior Director, Business Development at Guardant Health where she led business collaborations with Pharmaceutical companies for the development and commercialization of Next Generation Sequencing Liquid Biopsy products, as well as Companion Diagnostic programs. She joined Guardant from Leica Biosystems where she served as Senior Director, Business Development, Pharma Partnerships. Previously, Dr. Riley held progressive roles with Qiagen, most recently as Director of Assay Development.
Dr. Riley’s career began at St. James’s University Hospital as a Clinical Genetics Scientist. She holds a Ph.D. in Bio-production & Characterization of Self-Assembling Peptides from the University of Leeds, UK, and a B.S in Molecular & Cellular Biology from the University of Huddersfield, UK.
About PathAI
PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine.
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego and Boston.